Table 1.
Characteristics of studies investigating the effects of maintenance of BCG
| First author, yr | Design, LOE | No. of Case/Control | Age Case/Control* | Disease category | Follow-up, mo Case/Control* | Strain | Treatment dose (mg) Maintenance/Induction |
|---|---|---|---|---|---|---|---|
| Badalament 1987 [23] |
RCT, 1b |
47/46 |
62.0/63.5 |
Superficial BCa |
22(3–44) |
Pasteur |
120/120 |
| Koga 2010 [18] |
RCT, 1b |
24/27 |
NA |
High-risk NMIBC |
26.5/28.7 |
Tokyo |
80/80 |
| Hinotsu 2011 [16] |
RCT, 1b |
41/42 |
NA |
Recurrent or multiple NMIBC |
24 |
Connaught |
80/40 |
| Lamm 2000 [22] |
RCT, 1b |
192/192 |
66.8/67.0 |
Recurrent Ta, T1 and CIS |
119.1/120.3 |
Connaught |
80/40 |
| Palou 2001 [21] |
RCT, 1b |
65/61 |
65.0/63.0 |
CIS and/or high grade BCa |
77.8(7–120) |
Connaught |
81/81 |
| Hudson 1987 [24] |
RCT, 1b |
21/21 |
60.0/62.0 |
Superficial BCa |
16.1±1.4 |
Pasteur |
120/120 |
| Andius 2004 [20] |
R, 2b |
52/80 |
74(31–96) |
NMIBC without CIS |
44(4–155) |
Danish/OncoTice |
NA |
| Okamura 2011 [17] |
R, 2b |
48/27 |
64.0/68.0 |
NMIBC without CIS |
102/66 |
Tokyo 172 |
80/80 |
| Decobert 2008 [19] | R, 2b | 31/40 | 64.3/69.5 | High-risk NMIBC | 31 | Pacis | 120/120 |
LOE Level of evidence, RCT Randomized-controlled trial, R Retrospective, NMIBC Non-muscle-invasive bladder cancer, BCa Bladder cancer, CIS Carcinoma in suit, NA Not available, Case/Control, BCG maintenance/Induction.
* Mean or median.